Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CDK6 a transcriptional regulator in AML

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.06.18
Views: 466

Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria

Dr Sexl speaks with ecancer at EHA 23 about the findings linking CDK6 to p53 regulation and transcription in AML.

While CDK4/6 inhibitors are being pursued as regulators of the cell cycle in breast and ovarian cancers, Dr Sexl highlights that CDK4 alone is active as a regulator in AML.

Dr Sexl also spoke with ecancer about JAK pathways in B cell lymphoma, coming soon.

Related videos

20.11.18

no rating
Nurse course: education sharing

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation